When was Shennon Biotechnologies founded?

Shennon Biotechnologies was founded in 2021 and raised its 1st funding round 2 years after it was founded.

Where is Shennon Biotechnologies located?

Shennon Biotechnologies is headquartered in San Francisco, United States.

Who is the current CEO of Shennon Biotechnologies?

Li Sun of Shennon Biotechnologies. They have also founded 1 company.

How many employees does Shennon Biotechnologies have?

As of May 31, 2026, the latest employee count at Shennon Biotechnologies is 16.

Is Shennon Biotechnologies a funded company?

Shennon Biotechnologies is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Mar 13, 2023.

When was the latest funding round of Shennon Biotechnologies?

Shennon Biotechnologies' latest funding was a $***** Seed round on Mar 13, 2023, with participation from 3 investors. Its primary sector is Immunology. In United States, the Immunology sector has seen $2.72B in funding in 2026 to date.

Where does Shennon Biotechnologies rank among its competitors?

Shennon Biotechnologies ranks 922nd amongst 3460 active competitors, of which 1192 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Shennon Biotechnologies?

Shennon Biotechnologies' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Shennon Biotechnologies - 2026 Company Profile, Team, Funding & Competitors

Shennon Biotechnologies is a seed company based in San Francisco (United States), founded in 2021 by Li Sun. It operates as a Developer of immune cell therapies against solid tumors and autoimmune disease. Shennon Biotechnologies has raised $13M in funding from DCVC. The company has 3460 active competitors, including 1192 funded and 815 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Key Metrics

Founded Year

2021

Location

San Francisco, United States

Stage

Seed

Total Funding

$13M in 1 round

Latest Funding Round

Seed, Mar 13, 2023, $*****

Investors

DCVC & 3 more

Ranked

922^nd among 3460 active competitors

Employee Count

16 as on May 31, 2026

Similar Companies

BeiGene & 967 more

View Shennon Biotechnologies' full profile

Shennon Biotechnologies has raised a total funding of $13M over 1 round. Its latest funding round was a Seed round on Mar 13, 2023 for $*****. 3 investors participated in its latest round. Shennon Biotechnologies has 4 institutional investors.

Here is the list of recent funding rounds of Shennon Biotechnologies:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 13, 2023	7438893	Seed	3853613	5252175	9352113	3711334

Access funding benchmarks and valuations. Sign up today!

View details of Shennon Biotechnologies's funding rounds and investors

The founders of Shennon Biotechnologies is Li Sun. Li Sun is the CEO of Shennon Biotechnologies.

Here are the details of Shennon Biotechnologies' key team members:

Li Sun: Founder/CEO of Shennon Biotechnologies.

View details of Shennon Biotechnologies's Founder profiles and Board Members

Shennon Biotechnologies' employee count trend

Shennon Biotechnologies has 16 employees as of May 26. Here is Shennon Biotechnologies's employee count trend over the years:

Employee count trend for Shennon Biotechnologies

Uncover Shennon Biotechnologies' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Shennon Biotechnologies include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Shennon Biotechnologies, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	Khosla Ventures, True North & 23 others	71/100
922nd	Shennon Biotechnologies 2021, San Francisco (United States), Seed	Developer of immune cell therapies against solid tumors and autoimmune disease	$13M	Foundation Capital, Future Ventures & 2 others	44/100